Cited 20 times in
Urgency to treat patients with chronic hepatitis C in Asia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 안상훈 | - |
dc.date.accessioned | 2018-07-20T08:12:22Z | - |
dc.date.available | 2018-07-20T08:12:22Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160962 | - |
dc.description.abstract | Chronic hepatitis C (CHC) infection poses a global healthcare burden, being associated with serious complications if untreated. The prevalence of hepatitis C virus (HCV) infection is highest in areas of Central, South, and East Asia; over 50% of HCV patients worldwide live in the region, where HCV genotypes 1b, 2, 3, and 6 are the most prevalent. Treatment outcomes for chronic hepatitis C vary by ethnicity, and Asian patients achieve higher sustained virologic response rates following interferon (IFN)-based therapy than non-Asians. However, low efficacy, poor safety profile, and subcutaneous administration limit the use of IFN-based therapies. Superior virologic outcomes have been observed with different classes of direct-acting antivirals (DAAs) alone or in combination, and several all-oral DAA regimens are available in Asia. These regimens have shown excellent efficacy and favorable tolerability in clinical trials, yet there is a need for further studies of DAAs in a real world context, particularly in Asia. Furthermore, IFN-free treatment may not be accessible for many patients in the region, and IFN-based regimens remain an option in some countries. There is a need to improve current clinical practices for HCV management in Asia, including effective screening, disease awareness, and prevention programs, and to further understand the cost-effectiveness of IFN-free regimens. The evolution of potent treatments makes HCV eradication a possibility that should be available to all patients. However, access to these therapies in Asian countries has been slow, primarily because of economic barriers that continue to present a hurdle to optimal treatment. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Blackwell Scientific Publications | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antiviral Agents/therapeutic use* | - |
dc.subject.MESH | Asia/epidemiology | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Health Care Costs | - |
dc.subject.MESH | Hepacivirus/genetics | - |
dc.subject.MESH | Hepatitis C, Chronic/drug therapy* | - |
dc.subject.MESH | Hepatitis C, Chronic/economics | - |
dc.subject.MESH | Hepatitis C, Chronic/epidemiology | - |
dc.subject.MESH | Hepatitis C, Chronic/prevention & control | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Interferons/therapeutic use* | - |
dc.subject.MESH | Prevalence | - |
dc.title | Urgency to treat patients with chronic hepatitis C in Asia | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Jia‐Horng Kao | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Rong‐Nan Chien | - |
dc.contributor.googleauthor | Mong Cho | - |
dc.contributor.googleauthor | Wan‐Long Chuang | - |
dc.contributor.googleauthor | Sook‐Hyang Jeong | - |
dc.contributor.googleauthor | Chen‐Hua Liu | - |
dc.contributor.googleauthor | Seung‐Woon Paik | - |
dc.identifier.doi | 10.1111/jgh.13709 | - |
dc.contributor.localId | A02226 | - |
dc.relation.journalcode | J01417 | - |
dc.identifier.eissn | 1440-1746 | - |
dc.identifier.pmid | 28005275 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.13709 | - |
dc.subject.keyword | Asia | - |
dc.subject.keyword | HCV clinical trials | - |
dc.subject.keyword | HCV treatment | - |
dc.subject.keyword | clinical | - |
dc.subject.keyword | hepatitis C | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.citation.volume | 32 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 966 | - |
dc.citation.endPage | 974 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.32(5) : 966-974, 2017 | - |
dc.identifier.rimsid | 60856 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.